NeuroSense Therapeutics

NeuroSense Advances PrimeC Toward Potential ALS Approval

TEL AVIV, Israel, Aug. 31, 2026 NeuroSense Therapeutics Ltd. announced an accelerated and capital-efficient development strategy for PrimeC, its...

By cGxPwire Editor
September 2, 2026

M&A

Ionis Partners with Recordati to Expand Zilganersen Globally

CARLSBAD, Calif., June 25, 2026 Ionis Pharmaceuticals has entered into a landmark global licensing agreement with Recordati to accelerate...

By cGxPwire Editor
June 29, 2026

Veterinary

Anivive Wins FDA Approval for First Oral Canine Lymphoma Drug

LONG BEACH, Calif., June 26, 2026 Anivive Lifesciences has achieved a landmark milestone after the U.S. Food and Drug...

By cGxPwire Editor
June 29, 2026

.Clinical

NeuroSense PrimeC Shows Positive Phase 2 Alzheimer’s Biomarker Data

CAMBRIDGE, Mass., June 25, 2026 NeuroSense Therapeutics Ltd. announced positive biomarker findings from its Phase 2 randomized, double-blind, placebo-controlled...

By cGxPwire Editor
June 27, 2026

.Clinical Bio-Pharma

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a late-clinical stage biotechnology company developing therapies for neurodegenerative diseases, has entered into a...